Evaluation of p24-based antiretroviral treatment monitoring in pediatric HIV-1 infection: Prediction of the CD4+ T-cell changes between consecutive visits

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 5, 2006, Pages 557-562

  Brinkhof, Martin W G ^a   Böni, Jürg ^b   Steiner, Felicitas ^b   Tomasik, Zuzana ^b   Nadal, David ^b   Schüpbach, Jörg ^b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

CD4+ T lymphocyte; p24 antigen; Pediatric HIV 1 infection; Prognostic marker; Resource poor settings; Treatment monitoring; Viral load

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONITORING; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MALE; MODELS, IMMUNOLOGICAL; MONITORING, IMMUNOLOGIC;

EID: 33646800547     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000209824.77784.2c     Document Type: Article

References (30)

1. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5(Suppl 2):61-86.
2. Mofenson LM. US Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep. 2002;51:1-38. quiz CE1-4.
3. Cassens U, Gohde W, Kuling G, et al. Simplified volumetric flow cytometry allows feasible and accurate determination of CD4 T lymphocytes in immunodeficient patients worldwide. Antivir Ther. 2004;9:395-405.
4. Janossy G, Jani IV, Bradley NJ, et al. Affordable CD4(+)-T-cell counting by flow cytometry: CD45 gating for volumetric analysis. Clin Diagn Lab Immunol. 2002;9:1085-1094.
5. Schupbach J. Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. Int Arch Allergy Immunol. 2003;132:196-209.
6. Crowe S, Turnbull S, Oelrichs R, et al. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis. 2003;37:S25-S35.
7. Jennings CL, Fiscus SA, Danilovic AD, et al. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol. 2005;43:5950-5956.
8. Stevens G, Rekhviashvili N, Scott LE, et al. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol. 2005;43:857-861.
9. Schupbach J. Measurement of HIV-1 p24 antigen by signal-amplification- boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Rev. 2002;4:83-92.
10. Schupbach J, Flepp M, Pontelli D, et al. Heat-mediated immune complex dissociation and enzyme-linked immunosorbent assay signal amplification render p24 antigen detection in plasma as sensitive as HIV-1 RNA detection by polymerase chain reaction. AIDS. 1996;10:1085-1090.
11. Boni J, Opravil M, Tomasik Z, et al. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 P24 antigen assay with heat-denatured plasma. AIDS. 1997;11:F47-F52.
12. Ledergerber B, Flepp M, Boni J, et al. Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. J Infect Dis. 2000;181:1280-1288.
13. Bürgisser P, Vernazza P, Flepp M, et al. Performance of five different assays for the quantification of viral load in subjects infected with various subtypes of HIV-1. J Acquir Immune Defic Syndr. 2000;23:138-144.
14. Nadal D, Böni J, Kind C, et al. Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric HIV-1 infection. J Infect Dis. 1999;180:1089-1095.
15. + T-lymphocyte level in adults. J Infect Dis. 2002;186:1181-1185.
16. Ribas SG, Ondoa P, Schupbach J, et al. Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J Virol Methods. 2003;113:29-34.
17. Pascual A, Cachafeiro A, Funk ML, et al. Comparison of an assay using signal amplification of the heat-dissociated p24 antigen with the Roche Monitor human immunodeficiency virus RNA assay. J Clin Microbiol. 2002;40:2472-2475.
18. Schupbach J, Boni J, Bisset LR, et al. HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;33:292-299.
19. Jennings CL, Danilovic AD, Burgess DL, et al. A Comparison of Two Non-RNA-Based Assays for the Quantitation of HIV. Poster # 03-A-3803-ASM. Presented at: 43rd ICAAC; Sept. 14-17, 2003; Chicago, Ill.
20. Respess RA, Cachafeiro A, Withum D, et al. Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings. J Clin Microbiol. 2005;43:506-508.
21. + T cell loss. J Acquir Immune Defic Syndr. 2005;40:250-256.
22. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/guidelines/adult/AA_032304.pdf, 2004.
23. + T-cell determinations in persons infected with human immunodeficiency virus (HIV). Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 1997;46:1-29.
24. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-160.
25. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255-268.
26. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
27. Stoeckli TC, Steffen-Klopfstein I, Erb P, et al. Molecular epidemiology of HIV-1 in Switzerland: evidence for a silent mutation in the C2V3 region distinguishing intravenous drug users from homosexual men. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2000;23:58-67.
28. Böni J, Pyra H, Gebhardt M, et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;22:174-179.
29. Sherman GG, Stevens G, Stevens WS. Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection. Pediatr Infect Dis J. 2004;23:173-176.
30. Zijenah LS, Tobaiwa O, Rusakaniko S, et al. Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 years. J Acquir Immune Defic Syndr. 2005;39:391-394.